No Data
No Data
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $117
Gilead Sciences (GILD) Gets a Buy From Mizuho Securities
Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110
30 U.S. Picks Based on Up Vs. Down EPS Revisions and Dividend Payouts
10 Stocks Defying Wall Street Turbulence to Kick off the Month of May
Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest
小粉红的papa : It seems that not many people pay attention to biopharmaceutical Stocks, it's quite niche.
Everyone only invests in Technology Stocks.